Singapore markets close in 6 hours 19 minutes
Straits Times Index
3,322.53 -3.75 (-0.11%) Nikkei
39,715.45 +542.30 (+1.38%) Hang Seng
18,081.75 +8.85 (+0.05%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
62,168.61 +1,588.45 (+2.62%) CMC Crypto 200
1,290.25 +41.13 (+3.29%)
BIIB Jun 2024 237.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 237.50 |
| Expiry date | 2024-06-28 |
| Day's range | 0.1500 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
ZacksIs the Options Market Predicting a Spike in Biogen (BIIB) Stock?
Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.
ZacksBiogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GlobeNewswireTOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen Cambridge, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted approval for TOFIDENCETM, a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idio
© 2024 Yahoo. All rights reserved.